Literature DB >> 17958849

A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts.

G Gross1, K-G Meyer, H Pres, C Thielert, H Tawfik, A Mescheder.   

Abstract

OBJECTIVE: Clinical efficacy and safety of Polyphenon(R) E, a defined green tea extract, in external genital warts.
DESIGN: Randomized, double-blind, placebo-controlled study for up to 12 weeks with a 12-week treatment-free follow-up.
SETTING: Twenty-eight hospitals and practices in Germany and Russia. PATIENTS: Two hundred forty-two outpatients (125 men, 117 women) with 2 to 30 warts (total wart area, 12-600 mm(2)). Intervention(s) Topical application of Polyphenon E 10% Cream, Polyphenon E 15% Ointment or placebo to all external genital warts three times a day. MAIN OUTCOME MEASURE(S): Measurement of total wart area and local reactions/adverse events.
RESULTS: For 15% ointment, statistically significant differences to placebo were achieved regarding complete clearance of all baseline external genital warts (61.0% vs. 40.5% in males, 56.8% vs. 34.1% in females; combined gender: P = 0.0066) and 75% to 100% clearance (80.8% vs. 51.8%; P = 0.0001) in both the intent-to-treat and per-protocol populations. For 10% cream, 53.8% males and 39.5% females achieved complete clearance. Recurrence rates 12 weeks after end of treatment were 10.6%, 11.8% and 10.3% for 15% ointment, 10% cream and placebo, respectively. Adverse events were observed in only 7.9% of patients, with no serious adverse events or deaths reported. Local skin reactions were generally mild to moderate and resolved with continued treatment without sequelae.
CONCLUSIONS: Polyphenon(R) E 15% ointment, composed of a defined green tea extract, proved to be efficacious and safe for both gender in the treatment of external genital warts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17958849     DOI: 10.1111/j.1468-3083.2007.02441.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  21 in total

1.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

2.  [Conservative treatment of anogenital HPV infections].

Authors:  G Gross
Journal:  Hautarzt       Date:  2011-01       Impact factor: 0.751

Review 3.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

4.  Cutaneous infections and infestations: new therapies.

Authors:  Emily C Keller; Kenneth J Tomecki
Journal:  J Clin Aesthet Dermatol       Date:  2011-12

Review 5.  Green and black tea in relation to gynecologic cancers.

Authors:  Lesley M Butler; Anna H Wu
Journal:  Mol Nutr Food Res       Date:  2011-05-19       Impact factor: 5.914

6.  Efficacy of pulsed dye laser treatment for common warts is not influenced by the causative HPV type: a prospective study.

Authors:  Yoseph Fichman; Assi Levi; Emmilia Hodak; Shlomit Halachmi; Sigal Mazor; Dana Wolf; Orit Caplan; Moshe Lapidoth
Journal:  Lasers Med Sci       Date:  2017-12-07       Impact factor: 3.161

Review 7.  [Polyphenon E. A new topical therapy for condylomata acuminata].

Authors:  G Gross
Journal:  Hautarzt       Date:  2008-01       Impact factor: 0.751

8.  Curative propensity of green tea extract towards hepatic fibrosis induced by CCl(4): A histopathological study.

Authors:  A M Safer; M Afzal; A Nomani; O Sosamma; S A Mousa
Journal:  Exp Ther Med       Date:  2012-03-02       Impact factor: 2.447

Review 9.  Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

Authors:  Shreya Kanodia; Diane M Da Silva; W Martin Kast
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

10.  Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.

Authors:  Richard Gilson; Diarmuid Nugent; Kate Bennett; Caroline J Doré; Macey L Murray; Jade Meadows; Lewis J Haddow; Charles Lacey; Frank Sandmann; Mark Jit; Kate Soldan; Michelle Tetlow; Emilia Caverly; Mayura Nathan; Andrew J Copas
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.